Cargando…

A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot Study

Coronavirus disease 2019 (COVID‐19) has spread worldwide. To date, no specific drug for COVID‐19 has been developed. Thus, this randomized, open‐label, controlled clinical trial (ChiCTR2000029853) was performed in China. A total of 20 mild and common COVID‐19 patients were enrolled and randomly assi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Zhigang, Luo, Hong, Yu, Zujiang, Song, Jingchao, Liang, Lan, Wang, Ling, Wang, Haiyu, Cui, Guangying, Liu, Yong, Wang, Jin, Li, Qingquan, Zeng, Zhaohai, Yang, Shengkun, Pei, Guangzhong, Zhu, Yonghui, Song, Wenbin, Yu, Wenquan, Song, Chuanjun, Dong, Lihong, Hu, Chuansong, Du, Jinfa, Chang, Junbiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Full Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404576/ https://www.ncbi.nlm.nih.gov/pubmed/35403380 http://dx.doi.org/10.1002/advs.202001435

Ejemplares similares

Azvudine (FNC): a promising clinical candidate for COVID-19 treatment
por: Yu, Bin, et al.
Publicado: (2020)

The first Chinese oral anti-COVID-19 drug Azvudine launched
por: Yu, Bin, et al.
Publicado: (2022)

Immune response induced by novel coronavirus infection
por: Sun, Ying, et al.
Publicado: (2022)

Alterations of the oral and gut mycobiome and cytokines during long-term follow-up of COVID-19 convalescents
por: Ren, Zhigang, et al.
Publicado: (2023)

The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
por: Wang, Haiyu, et al.
Publicado: (2020)

Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants
por: Zhang, Xi, et al.
Publicado: (2023)

Inflammatory predictors (eosinophil, C-RP and IL-6) and effectiveness of oral Azvudine tablets treatment in COVID-19 hospitalized patients: A retrospective, self-controlled study
por: Zhao, Yanli, et al.
Publicado: (2023)

Serum metabolome alterations in patients with early nonalcoholic fatty liver disease
por: Wang, Xuemei, et al.
Publicado: (2022)

Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
por: Dian, Yating, et al.
Publicado: (2023)

Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19
por: Gao, Yuan, et al.
Publicado: (2023)

Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients
por: Zhang, Jin-Lan, et al.
Publicado: (2021)

Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis
por: Chen, Zhaoyan, et al.
Publicado: (2023)

Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine
por: Mao, Manyun, et al.
Publicado: (2023)

Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study
por: Zong, Kaican, et al.
Publicado: (2023)

Glycogen Phosphorylase B Is Regulated by miR101-3p and Promotes Hepatocellular Carcinoma Tumorigenesis
por: Cui, Guangying, et al.
Publicado: (2020)

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
por: Zhao, Xiang, et al.
Publicado: (2023)

Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients
por: de Souza, Sávio Bastos, et al.
Publicado: (2023)

Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study
por: Sun, Yuming, et al.
Publicado: (2023)

Alterations in the human oral and gut microbiomes and lipidomics in COVID-19
por: Ren, Zhigang, et al.
Publicado: (2021)

Dysbiosis in the Human Microbiome of Cholangiocarcinoma
por: Rao, Benchen, et al.
Publicado: (2021)

Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials
por: Zhu, Ke-Wei
Publicado: (2023)

An anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning
por: Guizhen, Zhang, et al.
Publicado: (2023)

All-cause mortality in moderate and severe COVID-19 patients with myocardial injury receiving versus not receiving azvudine: a propensity score-matched analysis
por: Chen, Ru, et al.
Publicado: (2023)

A novel predicted model for hypertension based on a large cross-sectional study
por: Ren, Zhigang, et al.
Publicado: (2020)

RPL19 Is a Prognostic Biomarker and Promotes Tumor Progression in Hepatocellular Carcinoma
por: Rao, Benchen, et al.
Publicado: (2021)

Nanosecond pulse effectively ablated hepatocellular carcinoma with alterations in the gut microbiome and serum metabolites
por: Zou, Yawen, et al.
Publicado: (2023)

Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
por: Zhao, Qinqin, et al.
Publicado: (2023)

Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching
por: Wei, An-Hua, et al.
Publicado: (2023)

Crosstalk Mechanisms Between HGF/c-Met Axis and ncRNAs in Malignancy
por: Liu, Xin, et al.
Publicado: (2020)

Potential Associations Between Microbiome and COVID-19
por: Wang, Huifen, et al.
Publicado: (2021)

Real-world effectiveness of azvudine for patients infected with the SARS-CoV-2 omicron subvariant BA.5 in an intensive care unit
por: Qi, Xiuping, et al.
Publicado: (2023)

Azvudine, A Novel Nucleoside Reverse Transcriptase Inhibitor Showed Good Drug Combination Features and Better Inhibition on Drug-Resistant Strains than Lamivudine In Vitro
por: Wang, Rui-Rui, et al.
Publicado: (2014)

Determination of the synergistic anti-influenza effect of Huangqin Su tablet and Oseltamivir and investigation of mechanism of the tablet based on gut microbiota and network pharmacology
por: Cui, Xuran, et al.
Publicado: (2023)

Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981]
por: Sun, Yuming, et al.
Publicado: (2023)

Fecal Microbiomes Distinguish Patients With Autoimmune Hepatitis From Healthy Individuals
por: Lou, Jiamin, et al.
Publicado: (2020)

Alterations in the human oral microbiota in systemic lupus erythematosus
por: Guo, Jinyan, et al.
Publicado: (2023)

Development of a model by LASSO to predict hospital length of stay (LOS) in patients with the SARS-Cov-2 omicron variant
por: Zhang, Jianxiang, et al.
Publicado: (2023)

Investigation on the Potential Application of Na-Attapulgite as an Excipient in Domperidone Sustained-Release Tablets
por: Xiao, Yuxuan, et al.
Publicado: (2022)

Formation Mechanism of Thicker Intermetallic Compounds in Friction Stir Weld Joints of Dissimilar AA2024/AZ31B Alloys
por: Tan, Maoju, et al.
Publicado: (2022)

Oral Fungal Alterations in Patients with COVID‐19 and Recovered Patients
por: Hu, Xiaobo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rh0i2meshl5puk5t497sgk2d7r